Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alfentanil Pre-medication for Hemodynamics in ECT
NCT03359395Phase 4Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- Jun 2018
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of alfentanil in major depressive disorder (MDD), sponsored by Wake Forest University Health Sciences. Started Jun 2018; status: completed.
02
Drugs
alfentanil
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03359395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03359395.